During my studies, I was especially drawn to biomarker discovery, focusing my Master’s thesis on investigating gene polymorphisms to improve cardiovascular drug safety.

To really understand how diseases form, I realised I needed to study the human body in depth, at cellular and molecular level.

During my master’s thesis, I investigated the WIP1/PPM1D phosphatase oncoprotein as a therapeutic target for potentiating p53-dependent therapies.

I’m particularly fascinated by how metabolic changes contribute to the transformation of normal T cells into malignant ones in ALCL. My current project dives into the role of STAT proteins

I started my science journey a few years ago with a Bachelor Degree in Biological Sciences at Eastern Piedmont University

My project focuses on uncovering and validating non-mutational mechanisms of resistance to ALK inhibitors in ALK-positive ALCL. While targeted therapies like ALK inhibitors have significantly improved patient outcomes, treatment resistance remains a major obstacle to long-term success.

Today, I’m a proud Marie Skłodowska-Curie Fellow under the EU Horizon Europe program—a fellowship that supports my work and enables international collaboration.

My name is Rebekka Salzmann, and I’m from Germany. During my Bachelor’s in Biology at the University of Hamburg, I became fascinated by the complex mechanisms that govern the small components of our bodies.